What Happened?
Shares of ophthalmology biopharmaceutical company Ocular Therapeutix (NASDAQ: OCUL) jumped 7.2% in the afternoon session after the company announced it reached an agreement with the U.S. Food and Drug Administration (FDA) on a plan to submit a New Drug Application (NDA) for its AXPAXLI injection.
The biopharmaceutical company plans to submit the application in the fourth quarter of 2026 for AXPAXLI as a treatment for wet age-related macular degeneration, a common eye condition. Reaching an alignment with the FDA on the submission strategy provides a clearer regulatory path forward for the drug. The application will be based on efficacy and safety data from the company's SOL-1 Phase 3 trial, along with interim safety data from its ongoing SOL-R trial. Ocular Therapeutix shared the update during an investor event.
Is now the time to buy Ocular Therapeutix? Access our full analysis report here, it’s free.
What Is The Market Telling Us
Ocular Therapeutix’s shares are extremely volatile and have had 39 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.
The biggest move we wrote about over the last year was 3 months ago when the stock gained 12.4% on the news that the company announced it had completed the first patient enrollment in the Phase III clinical trial for its dry eye disease treatment, OT-211, in China.
The treatment, OT-211 (AR-15512), is a 0.003% concentration eye drop formulation. It is also the first TRPM8 agonist approved by the U.S. Food and Drug Administration for this condition. According to the announcement, the successful enrollment of the first patient marked a significant milestone in the clinical development of OT-211 in China. The company stated this event reflected its commitment to advancing innovative therapies for patients suffering from dry eye disease.
Ocular Therapeutix is down 19.1% since the beginning of the year, and at $9.57 per share, it is trading 40.6% below its 52-week high of $16.11 from December 2025. Investors who bought $1,000 worth of Ocular Therapeutix’s shares 5 years ago would now be looking at only $709.04.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
